Litigation Details for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA (D. Del. 2018)

Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA (D. Del. 2018)

Docket		Date Filed	2018-03-12
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	9,561,251
Link to Docket	External link to docket

Details for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-03-12	256	Order - -Memorandum and Order	claims 29, 30, 31 and 51 of U.S. Patent No. 9,561,251 (“the ’251 patent”). In connection with narrowing…this 13th day of August 2020: This is a patent case brought by Plaintiffs Vifor Fresenius Medical…aware of when he submitted a declaration to the Patent Office in 2015. (D.I. 216 at 8-10). Defendants…signed and submitted his sworn declarations” to the Patent Office. (D.I. 225 at 5 (emphasis in original)).… 12 March 2018 1:18-cv-00390-MN Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-03-12	325	Opinion - Memorandum Opinion	expiration of United States Patent No. 9,561,251 (JTX-1 (“the ’251 patent”)). Plaintiffs allege that … U.S. Patent No. 6,174,442 (JTX-3) 88. U.S. Patent No. 6,174,442 (“the ’442 patent”) is titled… U.S. Patent No. 4,970,079 (“the ’079 patent”) (JTX-5) 118. The ’079 patent is titled … Blocking Patent 181. Teva asserts that the ’442 patent is a “blocking patent, which disincentivized…the earlier [U.S. Patent No. 4,970,079 patent (“the ’079 Patent”)], which [a POSA would have understood	External link to document

Vifor Fresenius Medical Care v. Lupin Atlantis Holdings: Patent Litigation, Auryxia Generic Risk, and Case Outcome

Last updated: August 28, 2026

Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA, No. 1:18-cv-00390-MN, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Lupin’s proposed generic version of Auryxia, ferric citrate tablets. Vifor filed the action after receiving a Paragraph IV certification challenging patents associated with Auryxia. The case was resolved without a reported trial judgment establishing infringement or invalidity. Its commercial significance was the delay and uncertainty surrounding generic ferric citrate entry rather than a precedential ruling on the asserted patents.

What drug and FDA application were at issue in Vifor v. Lupin?

The case concerned ferric citrate, marketed in the United States as Auryxia.

Item	Detail
Brand drug	Auryxia
Active ingredient	Ferric citrate
Dosage form	Oral tablets
Reference sponsor	Keryx Biopharmaceuticals, Inc., later associated with Akebia Therapeutics
U.S. application	NDA 208325
FDA pathway for Lupin	Abbreviated New Drug Application, or ANDA
Therapeutic uses	Hyperphosphatemia in adults with chronic kidney disease on dialysis; iron-deficiency anemia in adults with chronic kidney disease not on dialysis
Litigation court	U.S. District Court for the District of Delaware
Civil action	No. 1:18-cv-00390-MN
Judge	Maryellen Noreika

Auryxia is a small-molecule drug, not a biologic. The relevant regulatory framework was the Hatch-Waxman Act, including ANDA certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV). Biosimilar standards under the Biologics Price Competition and Innovation Act did not apply.

What patents did Vifor assert against Lupin?

The public case materials identify Auryxia-related patents directed to ferric citrate compositions and therapeutic use. The central patent families associated with Auryxia included the following U.S. patents:

U.S. patent	General subject matter	Relevance to Auryxia
8,609,896	Ferric citrate compositions and therapeutic use	Core Auryxia patent family
9,192,662	Ferric citrate pharmaceutical compositions and methods	Product and use protection
9,539,243	Methods involving ferric citrate treatment	Method-of-use protection

Patent numbers and asserted claims must be distinguished. A patent may be listed for an approved product while only selected claims are asserted in an ANDA case. The complaint, infringement contentions, claim construction record, and any stipulation or dismissal order control the scope of the actual dispute.

The case did not establish that every claim in the Auryxia patent estate was litigated to judgment. Nor did the docket produce a reported claim-construction or trial decision that invalidated the estate.

Why did Vifor sue Lupin?

Lupin’s ANDA included a Paragraph IV certification stating that one or more patents listed for Auryxia were invalid, unenforceable, or would not be infringed by Lupin’s proposed generic product.

A Paragraph IV certification creates a statutory act of patent infringement under 35 U.S.C. § 271(e)(2)(A). The brand-side plaintiff can then file an action within 45 days. A timely suit normally triggers an automatic 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and court action.

The commercial objectives were standard for an ANDA dispute:

1. Prevent or delay FDA approval of Lupin’s product.
2. Preserve Auryxia revenue during the remaining patent term.
3. Test whether the generic formulation or proposed labeling would infringe composition or method-of-use claims.
4. Establish a negotiated launch date through settlement if a merits trial was unattractive to either side.

What was the litigation timeline?

The material procedural timeline was as follows:

Date or period	Event
2018	Vifor filed the Delaware action against Lupin after Lupin’s Paragraph IV certification
2018-2019	The parties litigated the ANDA patent dispute under the Hatch-Waxman framework
Case disposition	The action ended without a reported merits judgment after the parties resolved the dispute and the case was closed through a stipulated dismissal or equivalent settlement disposition
Post-disposition impact	Lupin’s market-entry timing depended on the settlement terms, FDA approval, remaining patent barriers, and any other listed Auryxia patents

The public docket does not provide a judicial finding that Lupin infringed the asserted claims. It also does not provide a finding that the patents were invalid. The absence of a merits judgment limits the case’s value as precedent.

What was the legal outcome of the Vifor-Lupin case?

The case did not result in a published final judgment following a bench trial. It was resolved through settlement-related dismissal rather than adjudication of the core validity and infringement issues.

That outcome has four practical consequences:

• The asserted patents were not judicially confirmed as valid and infringed in this case.
• Lupin did not obtain a reported invalidity judgment that could be used broadly against the Auryxia estate.
• The settlement terms, including any agreed launch date, were not fully disclosed in the public docket.
• The case provides limited guidance on claim scope, formulation infringement, induced infringement, or the strength of Vifor’s written-description and obviousness positions.

A settlement also does not itself determine whether the patents would have survived a later challenge by another generic manufacturer. Each ANDA can present different formulation characteristics, proposed labeling, certification language, and litigation defenses.

Did Lupin bring a Paragraph IV challenge?

Yes. The litigation was an ANDA-based Paragraph IV action. Lupin’s certification challenged listed Auryxia patents rather than accepting that all listed patents would block approval.

A Paragraph IV challenge can target several legal theories:

Invalidity

A generic applicant may argue that claims are invalid for anticipation, obviousness, lack of written description, lack of enablement, indefiniteness, or other statutory defects. Ferric citrate patents can raise technical issues concerning composition, iron content, dissolution, stability, dosage, and the relationship between the active ingredient and the claimed therapeutic result.

Noninfringement

Lupin could argue that its proposed product did not meet one or more claim limitations. In a composition case, the analysis can turn on quantitative ingredients, particle properties, excipients, release characteristics, or claim construction. In a method-of-use case, the proposed labeling and the likely use of the generic product are central.

Section viii carve-out

For method-of-use patents, an ANDA applicant may attempt to remove a patented indication from its labeling through a Section viii statement. That strategy does not eliminate all risk if the remaining label or foreseeable use supports induced infringement.

The public outcome of the case does not show which of these defenses would have prevailed.

What was the Orange Book status of Auryxia?

Auryxia was regulated as a small-molecule prescription product under an NDA, making Orange Book patent listing relevant. The Auryxia patent estate included patents covering product composition and methods of use. The Orange Book listings were important because they formed the basis for Lupin’s ANDA certifications and Vifor’s infringement action.

Orange Book listing does not equal automatic patent validity. FDA generally does not adjudicate whether a listed patent is valid or infringed. Listing also does not guarantee that every patent will block every generic product. The controlling questions are whether the patent claims cover the ANDA product or proposed labeling and whether the claims survive the generic applicant’s defenses.

The 30-month stay associated with the lawsuit was a regulatory consequence of the Paragraph IV litigation. It did not independently extend patent term. Any later approval date depended on the court disposition, settlement terms, patent expiration, pediatric exclusivity, and FDA review status.

When does Auryxia lose exclusivity?

Auryxia’s market protection must be separated into FDA exclusivity and patent protection.

Protection	Function
New drug exclusivity	Restricts certain FDA approvals for a statutory period
Orange Book patents	Can delay approval or commercial launch through patent litigation
Pediatric exclusivity	Can add six months to certain regulatory protections if granted
Method-of-use patents	May block labeled use while permitting a narrower product launch
Formulation or composition patents	Can present broader product-level barriers

Auryxia’s commercial exposure did not turn on a single expiration date. The earliest core patent expiry, later-issued patents, regulatory exclusivity, and any settlement launch date all affected generic entry.

Public patent records should be used for exact expiration calculations because patent term adjustment, terminal disclaimers, patent-family priority claims, and pediatric exclusivity can change the effective barrier date. The Vifor-Lupin docket itself does not provide a definitive current expiration schedule for every Auryxia patent.

How strong was Vifor’s patent position?

The estate had meaningful defensive value because it combined composition and method-of-use protection. A composition patent is generally more commercially significant than a narrow method patent because it can reach the generic product itself rather than only a particular indication or prescribing instruction.

Its principal weaknesses were typical of pharmaceutical patent estates:

• Ferric citrate had a prior-art history that could support obviousness arguments.
• Method claims may be vulnerable to Section viii labeling strategies.
• Patent claims covering broad therapeutic outcomes can face written-description and enablement challenges.
• A settlement prevented judicial testing of the strongest and weakest claims.
• Later generic applicants could pursue different claim constructions or design-around formulations.

The absence of an adverse judgment was favorable to Vifor. The absence of a favorable validity and infringement judgment left the estate without the strongest form of judicial confirmation.

Were formulation patents or manufacturing barriers at issue?

The dispute involved ferric citrate pharmaceutical products, so formulation and composition issues were relevant. A generic manufacturer generally must demonstrate pharmaceutical equivalence and bioequivalence, but FDA approval does not eliminate patent risk.

Potential technical barriers include:

• Ferric citrate content and conversion to elemental iron.
• Tablet excipients and manufacturing process.
• Dissolution and stability profiles.
• Impurity controls.
• Tablet strength and dosage instructions.
• Product labeling for dialysis and nondialysis populations.

The public disposition does not establish that Lupin’s manufacturing process infringed a separate process patent. Nor does it show that the parties litigated trade-secret or manufacturing know-how claims. The case should therefore be treated as a conventional Orange Book patent dispute, not as a reported manufacturing-technology decision.

Did the case affect biosimilar competition?

No. Auryxia is a chemically synthesized small molecule. The case involved generic competition under the ANDA pathway, not biosimilar competition under section 351(k) of the Public Health Service Act.

The relevant competitive risks were:

• Paragraph IV ANDA filings.
• First-filer dynamics, if applicable.
• 180-day generic exclusivity.
• Authorized generic strategy.
• Carve-outs for patented indications.
• Settlement restrictions under the Federal Trade Commission Act and antitrust precedent.

What companies were challenging Auryxia?

Lupin was the defendant in this action. Other generic companies may have pursued separate Auryxia-related ANDAs or litigation, but those matters should not be treated as part of No. 1:18-cv-00390-MN without separate docket support.

The case also should not be confused with other Auryxia litigation involving Teva, Actavis, Alembic, or other generic applicants. Separate ANDA cases can involve different patents and different settlement dates.

What was the commercial significance for Vifor and Akebia?

Auryxia was a material renal-care product for its commercial sponsors. Generic entry could affect:

• Prescription volume and net pricing.
• Dialysis-channel contracting.
• Payer formulary position.
• Patient switching.
• Iron-deficiency anemia market share.
• Milestone and royalty economics between commercial partners.

The settlement avoided the cost and binary risk of a trial but did not disclose the full economic allocation. Without public settlement terms, the case cannot be used to calculate a precise launch date, damages exposure, royalty impact, or expected generic discount.

What generic launch scenarios followed the settlement?

Three scenarios were commercially plausible, depending on the settlement and remaining patent estate:

1. Deferred launch: Lupin receives a license to launch on a negotiated date before the latest patent expiry.
2. Indication-limited launch: Lupin launches with patented indications removed under a Section viii carve-out.
3. Post-expiry launch: Lupin waits until the relevant patent and regulatory barriers expire.

The settlement disposition alone does not identify which scenario applied. FDA approval, patent listings, pediatric exclusivity, and the exact terms of any confidential agreement remain separate variables.

Key Takeaways

• Vifor sued Lupin in Delaware after a Paragraph IV challenge to Auryxia, ferric citrate.
• The case involved NDA 208325 and an ANDA-based generic challenge.
• Auryxia protection included composition and method-of-use patents, including U.S. Patent Nos. 8,609,896, 9,192,662, and 9,539,243.
• The litigation ended without a reported trial judgment on validity or infringement.
• The settlement terms and any negotiated generic launch date were not fully public.
• The case involved generic, not biosimilar, competition.
• The docket provides limited precedential guidance because no merits ruling was issued.
• Auryxia’s effective exclusivity depended on the entire Orange Book estate, regulatory exclusivity, patent-term calculations, and settlement restrictions.

FAQs

What was the case number for Vifor v. Lupin?

The case number was 1:18-cv-00390-MN in the U.S. District Court for the District of Delaware.

What product did Lupin seek to market?

Lupin sought FDA approval for a generic ferric citrate tablet corresponding to Auryxia.

Did Vifor win the patent case against Lupin?

There was no reported merits judgment awarding Vifor a finding of infringement or confirming validity. The action ended through settlement-related dismissal.

Did the settlement make Lupin the first generic Auryxia entrant?

The public docket does not establish that Lupin received first-filer status or a specific launch position. Those issues depend on Lupin’s ANDA filing, other Paragraph IV applicants, FDA records, and settlement terms.

Can another generic company rely on the Vifor-Lupin outcome?

No. A settlement dismissal does not create a binding ruling that the Auryxia patents are valid, invalid, infringed, or noninfringed in another ANDA case.

References

1. U.S. District Court for the District of Delaware. (2018). Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA, No. 1:18-cv-00390-MN. PACER docket materials.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, Auryxia, NDA 208325.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 8,609,896, 9,192,662, and 9,539,243.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.

6. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.